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Summary 
Background: Since the rise in plasma adiponectin levels in
chronic kidney disease (CKD) patients has not yet been
elucidated, we sought to investigate if patients on hemo -
 dialysis (HD) have altered expression of adiponectin recep-
tors in peripheral blood mononuclear cells (PBMCs) com-
pared to healthy subjects.
Methods: This study included 31 patients with chronic kid-
ney disease on HD and 33 healthy subjects (CG). Circu -
lating adiponectin levels were measured by ELISA while
AdipoR1 and AdipoR2 mRNA levels in PBMCs were deter-
mined by real-time PCR.
Results: Plasma adiponectin levels were significantly higher
in patients compared to control group (P=0.036). After
adjustment for age, BMI and creatinine, this difference
became even more significant (P=0.004). In both groups
adiponectin correlated with creatinine (CG: r=-0.472,
P=0.006; HD: r=-0.375, P=0.038), triglycerides (CG: r=-
0.490, P=0.004; HD: r=-0.488, P=0.005), insulin (CG:
r=-0.386, P=0.038; HD: r=-0.506, P=0.012) and high
density lipoprotein cholesterol (HDL-C) (CG: r=-0.672,
P<0.001; HD: r=-0.584, P=0.001). Significantly lower
expression of PBMCs AdipoR1 mRNA was found in patients
compared to CG (P=0.034), while AdipoR2 mRNA levels
were similarly expressed in PBMCs in both groups.
Conclusions: Complex pathological processes in CKD
cause downregulation of AdipoR1 which could ultimately
influence AdipoR1 protein levels leading to a state of
»adiponectin resistance«.
Keywords: adiponectin, AdipoR1, AdipoR2, chronic
kidney disease
Kratak sadr`aj
Uvod: S obzirom na to da razlozi povi{enih vrednosti adipo -
ne ktina u hroni~noj bubre`noj insuficijenciji (HBI) jo{ uvek
nisu raz ja{njeni, cilj ovog istra`ivanja bio je da se ispita da li
pacijenti na hemodijalizi (HD) imaju promenjen nivo genske
eks pre sije adiponektinskih receptora u mono nu klea r nim }e -
lijama periferne krvi u odnosu na zdrave ispi tanike. 
Metode: Ova studija je obuhvatila 31 pacijenta sa hro ni~nom
bubre`nom insuficijencijom na hemodijalizi (HD) i 33 zdrava
ispitanika (KG). Koncentracija cirkuli{u}eg adi po nektina
odre |ena je ELISA metodom, a nivoi iRNK adi ponektinskih
receptora AdipoR1 i AdipoR2 u mono nu klear nim }elijama
periferne krvi odre|eni su metodom real-time PCR. 
Rezultati: Koncentracija adiponektina u plazmi pacijenata
bila je zna~ajno vi{a u odnosu na zdrave ispitanike (P=
0,036). Nakon korekcije za godine, BMI i kon cen tra ciju
kreatinina, ova razlika je postala jo{ zna~ajnija (P=0,004). U
obe grupe ispitanika koncentracija adiponektina je ko re -
lisala sa koncentracijom kreatinina (KG: r=-0,472,
P=0,006; HD: r=-0,375, P=0,038), koncentracijom tri -
gli ce rida (KG: r=-0,490, P=0,004; HD: r=-0,488,
P=0,005), koncentracijom insulina (KG: r=-0,386,
P=0,038; HD: r=-0,506, P=0,012) i koncentracijom
holeste rola u lipo proteinima velike gustine (KG: r=-0,672,
P<0,001; HD: r=-0,584, P=0,001). Pacijenti su imali
zna~ajno ni`i nivo iRNK AdipoR1 u mononuklearnim
}elijama periferne krvi u pore|enju sa zdravim ispitanicima
(P=0,034), dok se nivo iRNK AdipoR2 nije zna~ajno
razlikovao me|u posmatranim grupama. 
Zaklju~ak: Kompleksni patolo{ki procesi u HBI izazivaju
nishodnu regulaciju AdipoR1 gena, {to bi moglo uticati na
nivo AdipoR1 proteina, vode}i u stanje »adiponektinske
rezistencije«. 
Klju~ne re~i: adiponektin, AdipoR1, AdipoR2, hroni~na
bubre`na insuficijencija
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Introduction
Adiponectin is a protein abundantly secreted by
adipose tissue (1). It is generally considered a mole-
cule with antiinflammatory, atheroprotective and
anti apoptotic effects which are mainly achieved via
activation of two ubiquitously expressed adiponectin
receptors, AdipoR1 and AdipoR2 (2). Activation of
AdipoR1 leads to increased sensitivity of peripheral
tissues to insulin, while AdipoR2 activation increases
fatty acid combustion (1, 2). Although the mecha-
nism is not well understood, it has been shown that
adiponectin via these two receptors also activates
ceramidase which is important for its antiapoptotic
effects (3).
Peripheral blood mononuclear cells (PBMC)
and macrophages express both AdipoR1 and Adipo -
R2 allowing adiponectin to affect directly their func-
tion. Under this influence, macrophages increase IL-
10 secretion and shift from the proinflammatory M1
to the antiinflammatory M2 phenotype (4, 5). It has
also been shown that adiponectin exerts protective
effects on kidneys by decreasing podocytes albumin
permeability in mice (6). It seems that adiponectin
downregulates podocytes NADPH oxidase production
via AdipoR1 thus decreasing oxidative stress in these
cells (7). Martinez et al. suggested that increased
oxid ative stress together with the altered gene ex -
pres sion of adiponectin receptors could be related to
increased insulin resistance in patients with end-stage
renal kidney disease (18).
Patients with chronic kidney disease (CKD) are
greatly exposed to high risk of cardiovascular disease
(CVD) mortality due to the presence of several tradi-
tional and nontraditional risk factors (8, 9). Previous
studies consistently reported that adiponectin levels
are increased in patients with CKD, but the reasons for
this phenomenon have remained unclear. Pos sible
explanations include metabolic changes in uremia, re -
duced adiponectin clearance by kidneys and changes
in ligand/receptor reactivity (10–12). Although it was
suggested that kidneys play an important role in
adipo nectin clearance, it has been shown that in suc-
cessful renal transplantation adiponectin levels do de -
 crease, but still remain higher compared to healthy
individuals (13). On the other hand, Halberg et al.
have demonstrated in their study that the main site of
adiponectin clearance is the liver, and that kidneys only
eliminate final degradation products (14). De spite the
generally known protective effects of adipo nectin, its
role in CKD seems to be controversial. While several
meta-analyses have linked higher adipo ne ctin levels in
CKD patients with lower risk of CVD mortality (15,
16), others have concluded that CVD mortality in CKD
patients is associated with increased adiponectin levels
(8).
Although numerous studies have indicated that
increased circulating adiponectin is indisputably asso-
ciated with CKD, the reasons for this rise still remain
unclear. Since impairment of the adiponectin/recep-
tor axis could contribute to the adiponectin rise, we
sought to investigate if patients on hemodialysis
(HD) have an altered expression of adiponectin
receptors in PBMCs compared to healthy subjects.
Materials and Methods
Subjects
Thirty-one patients (19 males and 12 females;
age range 27–76 years, age median 58 years) with
CKD on hemodialysis were recruited from the
Nephrology Clinic, Clinical Center of Serbia. The
main causes of CKD in these patients were: chronic
glomerulonephritis (n=6), chronic renal insufficiency
(n=4), nephroangiosclerosis (n=6), uric acid ne -
phro pathy (n=2), Good-Pasture syndrome (n=2),
renal calculosis (n=2), vesicoureteral reflux (n=2),
hypertension (n=1), atrophia renis segmentalis
(n=1), lupus nephritis (n=1), endemic nephropathy
(n=1), chronic pyelonephritis (n=1), renal tubercu-
losis (n=1), renal vasculitis (n=1). The duration of
hemodialysis ranged from 3 to 248 days, with an
average of 90 days.
Thirty-three healthy subjects (15 males and 18
females; age range 27–60, age median 45) were
selected for the control group. They were interviewed
about their family history and health status. Inclusion
criteria for the control group were absence of cardio-
vascular diseases in family history; absence of hyper-
tension (diastolic blood pressure < 90 mm Hg
and/or systolic blood pressure < 140 mm Hg)
and/or absence of any antihypertensive therapy;
favorable lipid profile (according to Adult Treatment
Panel III guidelines – ATP III); glucose < 6.1 mmol/L;
IMT in at least one carotid artery < 1 mm.
The study was conducted according to the
guidelines laid down in the Declaration of Helsinki.
All the procedures involving human subjects were
approved by the Ethical Committee of the Faculty of
Pharmacy, University of Belgrade and School of
Medicine, Uni versity of Belgrade. All the participants
have signed an informed consent before the enrol-
ment.
Samples
Blood samples were collected after a 12-hour
fasting period into EDTA-containing tubes. Whole
blood was centrifuged for 10 min at 3000 rpm; plas-
ma was separated, frozen and stored at –80 °C until
analysis. PBMCs from whole blood were isolated
using Ficoll-Paque® gradient and immediately added
to TRIzol™ extraction (Invitrogen Life Technologies,
Carlsbad, CA, USA) (TRI) reagent and then stored
–80 °C until RNA isolation.
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Analytical methods
Glucose, total cholesterol (TC), HDL-cholesterol
(HDL-C), LDL-cholesterol (LDL-C), triglycerides (TG),
urea, creatinine were measured by routine enzymatic
methods in plasma using an ILab 300+ analyzer
(Instrumentation Laboratory, Milan, Italy) and Ran -
dox Laboratories (Armdore, UK) reagents. Fasting
insulin concentration was measured by the ECLIA
method, on a COBAS®INTEGRA 400 plus – Roche
Diagnostics.
In the plasma of all subjects, circulating adipo -
nectin was measured using a Human Total Adipo -
nectin/Acrp30 Quantikine ELISA Kit. Sensitivity of this
assay was 0.891 ng/mL, intra-assay and inter-assay
coefficients of variation were 3.4% and 5.8% respec-
tively. All the samples were measured in duplicates.
Methods used for RNA isolation, reverse tran-
scription and real-time PCR were described in detail
elsewhere (17). Briefly, RNA was isolated using a
TRIzol™ extraction (Invitrogen Life Technologies,
Carls bad, CA, USA) (TRI) reagent according to man-
ufacturer’s protocol and quantified by absorbance
spectrometry at 260 nm. In order to estimate orga -
nic and protein contamination, in every sample
absor bance was measured at 230 nm and 280 nm,
res pe ctively. RNA integrity was evaluated by elec-
trophoresis on 1% agarose gel. Reverse transcription
and real-time PCR experiments were performed on
the 7500 Real-Time PCR System (Applied Bio sys -
tems, Foster City, CA, USA) using TaqMan® rea -
gent-based che mistry. Data were expressed as a ratio
between the target gene mRNA level and the mRNA
level of the housekeeping gene (beta-actin).
Statistical analysis
Statistical analysis was performed using IBM®
SPSS® Statistics version 22 software. Distribution of
data was tested with the Shapiro-Wilk test. Normally
distributed data are presented as mean ± standard
deviation. For the non-normally distributed data log-
arithmic transformation was performed and these
data are presented as geometrical means and 95%
confidence intervals. If data could not be transfor -
med to fit normal distribution they are presented as
medians and interquartile ranges. Statistical tests
used for normally distributed data were: Pearson’s
correlation, independent samples t-test and ANOVA.
Adjust ments were performed by using the analysis of
covariance (ANCOVA). For the data that had not
been normally distri buted, Mann-Whitney U test and
Spearman’s correlation were used. Chi-square test
was used for the comparison of categorical variables.
Statistically sig nifi cant p-value was less than 0.05.
Results
Anthropometric and biochemical data of healthy
subjects and patients on HD are presented in Table I.
Levels of urea, creatinine, TG, HDL-C and hsCRP as
well as IMT were increased in HD patients compared
to healthy subjects (P<0.001, P<0.001, P=0.006,
P<0.001, P<0.001, P<0.001, respectively). Levels
of insulin were also significantly higher in patients
compared to control subjects (P<0.001). On the
contrary, BMI and TC were significantly higher in the
control group (P=0.001, P=0.047, respectively),
while LDL-C levels showed no difference between
the groups (P=0.084).
CG HD P
Male/female 15/18 19/12 0.132***
Age (years) 45±9 55±15 0.003*
BMI (kg/m2) 24.9±3.6 22.2±3.0 0.002*
Urea (mmol/L) 5.76 (5.33–6.23) 21.16 (19.60–22.84) <0.001*
Creatinine (mmol/L) 86.5 (82.7–90.4) 982.4 (929.4–1038.4) <0.001*
TC (mmol/L) 5.07±0.92 4.60±0.94 0.047*
HDL-C (mmol/L) 1.60 (1.47–1.75) 0.85 (0.76–0.95) <0.001*
LDL-C (mmol/L) 3.09±0.76 2.73±0.83 0.084*
TG (mmol/L) 1.24 (1.06–1.47) 1.75 (1.46–2.11) 0.006*
hsCRP (mg/L) 1.16 (0.71–1.45) 5.20 (2.62–11.17) <0.001**
Insulin (mU/L) 8.90±3.48 42.29±39.91 <0.001*
Adiponectin (mg/mL) 9.60 (7.64–12.04) 13.42 (10.72–16.80) 0.036*
IMT (mm) 0.45 (0.00–0.50) 0.65 (0.55–0.70) <0.001**
Table I Basic anthropometric, lipid status, inflammation parameters in healthy children according to the age subgroups.
Urea, Creatinine, HDL-C, TG, adiponectin and IMT are logarithmically transformed before statistical analysis and presented as geo-
metrical mean and 95% confidence intervals (CI). Age, BMI, TC and LDL-C are presented as mean ± standard deviation.
*Variables were compared by Student’s t-test.
**Variables were compared by Mann-Whitney U test.
***Variables were compared by Chi-square test.
Plasma adiponectin levels were significantly
higher in patients compared to control group
(P=0.036, Table I). After adjustment for age, BMI
and creatinine, this difference became even more
significant (P=0.004). Males had significantly lower
adiponectin levels than females in the control group
(6.26 (4.76–8.22) mg/mL vs. 13.70 (10.55–17.80)
mg/mL, p<0.001) as well as in the patient group
(10.54 (8.17–13.60) mg/mL vs. 19.84 (14.79–
26.63) mg/mL, P=0.004). After adjustment for BMI
these differences remained significant (P=0.009,
P=0.003, respectively).
Furthermore, significantly lower expression of
PBMCs AdipoR1 mRNA was found in patients com-
pared to healthy subjects (P=0.034), while AdipoR2
mRNA levels were similarly expressed in PBMCs in
both groups (Figure 1). We have found a strong cor-
relation between adiponectin receptors in CG (r=
0.666, P<0.001). However, correlation between the
two adiponectin receptors was not demonstrated in
the patient group (r=-0.061, P=0.757). We have
also demonstrated a significant negative correlation
between AdipoR1 mRNA levels and insulin concen-
tration, but only in the patient group (r=-0.469,
P=0.021).
Correlations of adiponectin with other parame-
ters, in healthy subjects and patients with CKD, are
presented in Table II. In both groups, adiponectin
negatively correlated with creatinine, insulin, TG, and
positively with HDL-C. Negative correlation was
observed between adiponectin and BMI only in the
control group.



























































Figure 1 Normalized AdipoR1 (A) and Adipor2 (B) mRNA
levels from PBMCs of healthy subjects (CG) and CKD patients
on hemodialysis (HD).
# – significantly different compared to healthy subjects;
P=0.034.
Table II Correlation of adiponectin and different parameters in healthy subjects (CG) and CKD patients on hemodialysis (HD).
*parameters were tested by Spearman's correlation analysis.
Adiponectin (mg/mL)
CG HD
r P r P
Age (years) 0.059 0.743 0.123 0.509
BMI (kg/m2) -0.613 <0.001 -0.193 0.317
Urea (mmol/L) 0.028 0.879 0.222 0.229
Creatinine (mmol/L) -0.472 0.006 -0.375 0.038
TC (mmol/L) 0.120 0.505 0.070 0.707
HDL-C (mmol/L) 0.672 <0.001 0.584 0.001
LDL-C (mmol/L) 0.192 0.293 0.157 0.415
TG (mmol/L) -0.490 0.004 -0.488 0.005
hsCRP (mg/L) -0.305 0.084 -0.356 0.074
Insulin (mU/L) -0.386 0.038 -0.506 0.012
IMT (mm) 0.162 0.483 0.105 0.561
AdipoR1* -0.041 0.822 0.131 0.481
AdipoR2* -0.131 0.468 -0.177 0.368
Discussion
In this study, we have shown that downregula-
tion of AdipoR1 mRNA in PBMCs (Figure 1) and
increase in circulating adiponectin levels are present
in CKD patients on hemodialysis (Table I). Patients
were significantly older than controls, but since age
did not significantly correlate with either adiponectin
or adiponectin receptors, we feel that the obtained
results were not influenced by the age difference
between the observed subjects.
Increased adiponectin levels in patients on
hemo dialysis were demonstrated in numerous stud-
ies over the past decade, but the reason(s) for this
rise have remained unclear. Although kidneys play an
important role in the elimination of adiponectin, its
elevated levels cannot solely be linked to the deteri-
oration of their function (18). It has been shown that
urinary adiponectin levels are also increased in
patients with CKD and that after successful kidney
transplantation adiponectin levels do decrease, but
still remain higher compared to healthy individuals
(13). Over production and secretion of adiponectin by
adipose tissue could be an important contributor to
its in crease in circulation, but data regarding this
subject are not consistent and require further clarifi-
cations. While Martinez et al. reported increased
expression of both adiponectin mRNA and protein in
visceral and subcutaneous fat tissue in patients with
end stage kidney disease (19), Marchlewska et al.
(20) demonstrated opposite results.
Another mechanism that could contribute to the
increase of adiponectin levels in HD patients is the
loss of its effects due to downregulation of its recep-
tors (21), which has already been demonstrated in
patients with chronic heart failure (CHF) (22) and
coronary artery disease (23). In our study, we have
found that patients on hemodialysis have decreased
expression of AdipoR1 mRNA in PBMCs compared to
healthy subjects (Figure 1). This implies that various
pathological processes in chronic kidney disease
cause downregulation of AdipoR1. Long term
decrease of AdipoR1 mRNA levels could ultimately
lead to decrease of AdipoR1 protein levels on cell sur-
face creating a possibility for the development of
»adiponectin resistance«.
Initial stimuli for this downregulation are still
unclear. Previous studies have suggested that
increased insulin levels are associated with CKD,
which was confirmed by our study. We have also
found a significant negative correlation between
AdipoR1 mRNA levels and insulin concentration but
only in patients which suggests that the observed
AdipoR1 downregulation could be partly attributed to
insulin. Previous studies have also underlined the
influence of insulin on AdipoR1 expression. Namely,
it has been shown that insulin leads to downregula-
tion of AdipoR1 expression, through the activation of
phosphoinositide 3-kinase (PI3-kinase)/Foxo1 path-
way (21). Moreover, a strong correlation between
the two adiponectin receptors was demonstrated
only in CG, while in patients on HD this connection
was lost. Hence, the downregulation of AdipoR1
could be a consequence of the pathological process-
es that act solely upon the regulation of the expres-
sion of AdipoR1, but not AdipoR2.
Our results are not in line with two previous
studies in which CKD patients had elevated expres-
sion of adiponectin receptors (19, 24). These dis-
crepancies could be a consequence of several fac-
tors. Patients in previous studies had higher BMI
(26.0±5.0 and 27.3±4.4 kg/m2) than patients in
our study (22.2±3.0 kg/m2). In line with this,
Tsigalou et al. showed that beneficial effects of high
adiponectin levels on survival were observed only in a
subgroup of HD patients with high BMI (>24 kg/m2)
which could be due to the upregulation of adipo -
nectin receptors in CKD patients with higher BMI
(25). Also, subjects in previous studies had been on
hemodialysis for a much longer period of time (aver-
age: 3.5 years) than our patients (average: 90 days).
And finally, in the study by Martinez et al. (19)
patients that had kidney transplantation as well as
patients with diabetes mellitus type two were includ-
ed, while in our study those subjects were excluded.
We have also shown that adiponectin is related
to lipid parameters in both groups, negatively with TG
and positively with HDL-C (Table II). Two previous
studies have shown that despite the fact that
adiponectin was positively associated with HDL-C,
high rather than low adiponectin was related to
increased all-cause mortality in CKD patients (17)
and increased all-cause mortality and progression to
end stage renal disease (ESKD) in type I diabetic
patients (26). Namely, patients with end stage kidney
disease often have altered HDL particles composi-
tion, leading to impaired functions of HDL and loss of
its antiatherogenic properties (27, 28) which is asso-
ciated with increased CVD risk (29).
It should be noted that the results presented in
this study have certain limitations. Firstly, generaliza-
tion of our conclusion is limited by the small sample
size and low statistical power, so a case-control study
including more subjects is needed to further elucidate
the relation between adiponectin and the develop-
ment of CKD. Secondly, various causes led to kidney
failure in these patients which could have also influ-
enced our results. Thirdly, we have only measured
mRNA levels of adiponectin receptors, but not their
protein levels which could have strengthened our
findings of the receptors downregulation.
In summary, our study has demonstrated down-
regulation of AdipoR1 and higher levels of circulating
adiponectin in CKD patients on hemodialysis. It
seems that, in such a complex milieu as one created
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during CKD, AdipoR1 is downregulated, which in
the long term could reduce AdipoR1 protein levels
thus leading to a state of »adiponectin resistance«.
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